Copyright
©The Author(s) 2016.
World J Gastrointest Oncol. Mar 15, 2016; 8(3): 297-304
Published online Mar 15, 2016. doi: 10.4251/wjgo.v8.i3.297
Published online Mar 15, 2016. doi: 10.4251/wjgo.v8.i3.297
Table 2 Clinical trials in metastatic pancreatic cancer associating two targeted therapies to chemotherapeutical agents
Ref. | Regimen | Phase | PFS | OS |
Van Cutsem et al[18] | Gemcitabine/erlotinib/bevacizumab Gemcitabine/erlotinib | III | 4.6 | 7.1 |
3.6 | 6.0 | |||
Philip et al[19] | Gemcitabine/erlotinib/cixutumumab Gemcitabine/erlotinib | I | 3.6 | 7.0 |
3.6 | 6.7 | |||
Watkins et al[20] | Gemcitabine/capecitabine/erlotinib/bevacizumab | I/II | 8.4 | 12.6 |
NCT02450656 (ongoing trial) | Afatinib/selumetinib | II | NA | NA |
Capecitabine |
- Citation: Kourie HR, Gharios J, Elkarak F, Antoun J, Ghosn M. Is metastatic pancreatic cancer an untargetable malignancy? World J Gastrointest Oncol 2016; 8(3): 297-304
- URL: https://www.wjgnet.com/1948-5204/full/v8/i3/297.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v8.i3.297